Gastrointestinal Stromal Tumor GIST - Pipeline Review H1 2016
'Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2016', gives a framework of the Gastrointestinal Stromal Tumor (GIST) pipeline scene. This report gives thorough information on the therapeutics a work in advancement for Gastrointestinal Stromal Tumor (GIST), complete with examination by period of progression, pharmaceutical target, instrument of action (MoA), course of association (RoA) and molecule sort. The report also covers the expressive pharmacological movement of the therapeutics, its complete imaginative work history and latest news and open articulations. Additionally, the report gives a graph of key players required in therapeutic headway for Gastrointestinal Stromal Tumor (GIST) and parts slow and stopped endeavors.
'Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2016', gives a framework of the Gastrointestinal Stromal Tumor (GIST) pipeline scene.
This report gives thorough information on the therapeutics a work in advancement for Gastrointestinal Stromal Tumor (GIST), complete with examination by period of progression, pharmaceutical target, instrument of action (MoA), course of association (RoA) and molecule sort. The report also covers the expressive pharmacological movement of the therapeutics, its complete imaginative work history and latest news and open articulations. Additionally, the report gives a graph of key players required in therapeutic headway for Gastrointestinal Stromal Tumor (GIST) and parts slow and stopped endeavors.
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>Gastrointestinal</strong> <strong>Stromal</strong> <strong>Tumor</strong> (<strong>GIST</strong>)<br />
- <strong>Pipeline</strong> <strong>Review</strong> <strong>H1</strong> <strong>2016</strong><br />
Telephone: +1 (800) 910-6452<br />
Mail at: sales@researchbeam.com
Report Overview<br />
‘<strong>Gastrointestinal</strong> <strong>Stromal</strong> <strong>Tumor</strong> (<strong>GIST</strong>) - <strong>Pipeline</strong> <strong>Review</strong>, <strong>H1</strong> <strong>2016</strong>’, provides an overview of the<br />
<strong>Gastrointestinal</strong> <strong>Stromal</strong> <strong>Tumor</strong> (<strong>GIST</strong>) pipeline landscape.<br />
The report provides comprehensive information on the therapeutics under development for<br />
<strong>Gastrointestinal</strong> <strong>Stromal</strong> <strong>Tumor</strong> (<strong>GIST</strong>), complete with analysis by stage of development, drug target,<br />
mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the<br />
descriptive pharmacological action of the therapeutics, its complete research and development history<br />
and latest news and press releases. Additionally, the report provides an overview of key players involved in<br />
therapeutic development for <strong>Gastrointestinal</strong> <strong>Stromal</strong> <strong>Tumor</strong> (<strong>GIST</strong>) and features dormant and<br />
discontinued projects.<br />
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy<br />
areas and nearly 3,000 indications. The report is built using data and information sourced from Global<br />
Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences,<br />
SEC filings, investor presentations and featured press releases from company/university sites and industryspecific<br />
third party sources. Drug profiles featured in the report undergoes periodic review following a<br />
stringent set of processes to ensure that all the profiles are updated with the latest set of information.<br />
Additionally, various dynamic tracking processes ensure that the most recent developments are captured<br />
on a real time basis.<br />
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances<br />
decision making capabilities and helps to create effective counter strategies to gain competitive<br />
advantage.<br />
Strategic Focus Report @ http://www.researchbeam.com/gastrointestinal-stromal-tumor-gist-pipelinereview-h1-<strong>2016</strong>-market
Report Overview<br />
Scope<br />
- The report provides a snapshot of the global therapeutic landscape of <strong>Gastrointestinal</strong> <strong>Stromal</strong> <strong>Tumor</strong><br />
(<strong>GIST</strong>)<br />
- The report reviews pipeline therapeutics for <strong>Gastrointestinal</strong> <strong>Stromal</strong> <strong>Tumor</strong> (<strong>GIST</strong>) by companies and<br />
universities/research institutes based on information derived from company and industry-specific sources<br />
- The report covers pipeline products based on various stages of development ranging from preregistration<br />
till discovery and undisclosed stages<br />
- The report assesses <strong>Gastrointestinal</strong> <strong>Stromal</strong> <strong>Tumor</strong> (<strong>GIST</strong>) therapeutics based on drug target,<br />
mechanism of action (MoA), route of administration (RoA) and molecule type<br />
Reasons to buy<br />
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D<br />
strategies<br />
- Identify emerging players with potentially strong product portfolio and create effective counterstrategies<br />
to gain competitive advantage<br />
- Identify and understand important and diverse types of therapeutics under development for<br />
<strong>Gastrointestinal</strong> <strong>Stromal</strong> <strong>Tumor</strong> (<strong>GIST</strong>)<br />
- Devise corrective measures for pipeline projects by understanding <strong>Gastrointestinal</strong> <strong>Stromal</strong> <strong>Tumor</strong> (<strong>GIST</strong>)<br />
pipeline depth and focus of Indication therapeutics
Table of Contents<br />
Table of Contents 2<br />
List of Tables 7<br />
List of Figures 8<br />
Introduction 9<br />
Global Markets Direct Report Coverage 9<br />
<strong>Gastrointestinal</strong> <strong>Stromal</strong> <strong>Tumor</strong> (<strong>GIST</strong>) Overview 10<br />
Therapeutics Development 11<br />
<strong>Pipeline</strong> Products for <strong>Gastrointestinal</strong> <strong>Stromal</strong> <strong>Tumor</strong> (<strong>GIST</strong>) - Overview 11<br />
<strong>Pipeline</strong> Products for <strong>Gastrointestinal</strong> <strong>Stromal</strong> <strong>Tumor</strong> (<strong>GIST</strong>) - Comparative Analysis 12<br />
<strong>Gastrointestinal</strong> <strong>Stromal</strong> <strong>Tumor</strong> (<strong>GIST</strong>) - Therapeutics under Development by Companies 13<br />
<strong>Gastrointestinal</strong> <strong>Stromal</strong> <strong>Tumor</strong> (<strong>GIST</strong>) - Therapeutics under Investigation by Universities/Institutes 15<br />
<strong>Gastrointestinal</strong> <strong>Stromal</strong> <strong>Tumor</strong> (<strong>GIST</strong>) - <strong>Pipeline</strong> Products Glance 16<br />
Late Stage Products 16<br />
Clinical Stage Products 17<br />
Early Stage Products 18<br />
<strong>Gastrointestinal</strong> <strong>Stromal</strong> <strong>Tumor</strong> (<strong>GIST</strong>) - Products under Development by Companies 19<br />
<strong>Gastrointestinal</strong> <strong>Stromal</strong> <strong>Tumor</strong> (<strong>GIST</strong>) - Products under Investigation by Universities/Institutes 21<br />
<strong>Gastrointestinal</strong> <strong>Stromal</strong> <strong>Tumor</strong> (<strong>GIST</strong>) - Companies Involved in Therapeutics Development 22<br />
Advenchen Laboratories, LLC 23<br />
Ariad Pharmaceuticals, Inc. 24<br />
Arog Pharmaceuticals, Inc. 25<br />
Array BioPharma Inc. 26<br />
Astex Pharmaceuticals, Inc. 27
Table of Contents<br />
Blueprint Medicines Corporation 28<br />
Boston Biomedical, Inc. 29<br />
Calithera Biosciences, Inc. 30<br />
Chipscreen Biosciences Ltd 31<br />
Deciphera Pharmaceuticals, LLC 32<br />
F. Hoffmann-La Roche Ltd. 33<br />
Horizon Pharma Plc 34<br />
Immunicum AB 35<br />
Jiangsu Hengrui Medicine Co., Ltd. 36<br />
Kolltan Pharmaceuticals, Inc. 37<br />
Natco Pharma Limited 38<br />
Nerviano Medical Sciences S.r.l. 39<br />
Novartis AG 40<br />
Omeros Corporation 41<br />
Plexxikon Inc. 42<br />
TG Therapeutics, Inc. 43<br />
Threshold Pharmaceuticals, Inc. 44<br />
<strong>Gastrointestinal</strong> <strong>Stromal</strong> <strong>Tumor</strong> (<strong>GIST</strong>) - Therapeutics Assessment 45<br />
Assessment by Monotherapy Products 45<br />
Assessment by Combination Products 46<br />
Assessment by Target 47<br />
Assessment by Mechanism of Action 50<br />
Assessment by Route of Administration 53
Report Ordering<br />
Report Name:<br />
<strong>Gastrointestinal</strong> <strong>Stromal</strong> <strong>Tumor</strong> <strong>GIST</strong> - <strong>Pipeline</strong> <strong>Review</strong><br />
<strong>H1</strong> <strong>2016</strong><br />
Product Price<br />
User<br />
Price<br />
Single User US $ 1700<br />
Site User US $ 4000<br />
Global User US $ 6000<br />
To View Sample or Purchase Report
Contact Us<br />
FOR MORE DETAILS<br />
Visit us at :<br />
http://www.researchbeam.com/gastrointestinal-stromal-tumor-gist-pipeline-review-h1-<strong>2016</strong>-market<br />
Stay With Us At:<br />
TELEPHONE: +1 (800) 910-6452<br />
DIRECT: +1 (503) 894-6022<br />
E-MAIL: sales@researchbeam.com<br />
5933 NE Win Sivers Drive,<br />
#205, Portland, OR 97220<br />
United States
Change language